Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere Trivalent Influenza Vaccine is associated with adverse events  by Rockman, Steve et al.
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In Australia,  during  the  2010  Southern  Hemisphere  (SH)  inﬂuenza  season,  there  was  an  unexpected
increase  in post-marketing  adverse  event  reports  of  febrile  seizures  (FS)  in children  under  5  years  of  age
shortly  after  vaccination  with  the  CSL  trivalent  inﬂuenza  vaccine  (CSL  2010  SH  TIV)  compared  to previous
CSL  TIVs  and other  licensed  2010  SH  TIVs.  The  present  study  describes  the outcomes  of  a  series  of  in  vitro
experiments  directed  at elucidating  the  root  cause.  The  scientiﬁc  investigations  found  that  a  subset  of
paediatric  donors  displayed  elevated  cytokine/chemokine  responses  to the  CSL  2010 SH  TIV  but  not  to
previous  CSL  TIVs  nor  other  2010  SH TIVs.  The  induction  of  elevated  cytokines/chemokines  in  paedi-
atric  whole  blood  correlated  with  elevated  NF-B  activation  in a HEK293  cell reporter  assay.  The data
indicate  that the  introduction  of  the  B/Brisbane/60/2008  strain  within  the  CSL manufacturing  process
(such  as  occurred  in  the preceding  2009/10  NH season)  appears  to have  raised  the  pyrogenic  potential
of  the CSL  2009/10  NH  TIV  but  that  this  was  insufﬁcient  to  elicit  FS  in  children  <5  years.  The  2010  SH
season  coincided  with  the  ﬁrst introduction  of the H1N1  A/California/07/2009  in  combination  with the
B/Brisbane/60/2008  strain.  Our data  demonstrates  that  the  introduction  of  the  H1N1  A/California/07/2009
(and  to a  much  lesser  degree,  H3N2  A/Wisconsin/15/2009)  in combination  with  B/Brisbane/60/2008  (as
expressed  through  the  CSL  method  of manufacture)  combined  and  likely  compounded  the  bioactivity
of  the  CSL  2010  SH TIV.  This  was  associated  with  stronger  immune  responses,  which  in a  proportion  of
children  <5  years  were  associated  with  FS.  The  assays  and  systems  developed  during  these  investiga-
tions  should  greatly  assist  in determining  the  bioactivity  of  new  inﬂuenza  strains,  and thus  aid  with  the
manufacture  of CSL  TIVs  indicated  for use in  the  paediatric  population.
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. Introduction
In 2010, the World Health Organisation (WHO) recommended
hree new strains for inclusion in the 2010 inﬂuenza vac-
ine intended for use in the Southern Hemisphere (SH) season:
/California/07/2009 (H1N1), A/Wisconsin/15/2009 (H3N2) and
/Brisbane/60/2008 (B-strain) [1]. All TIVs, irrespective of manufac-
urer, contain similar amounts of antigen based on haemaggutinin
HA) content (7.5 g per strain per dose for children 6 months–3
ears and 15 g per strain per dose for children above three years
nd adults). Methods of manufacture for all registered inactivated
nﬂuenza vaccines are unique to each manufacturer [2].
In the 2010 SH season, CSL’s 2010 SH TIV (CSL 2010 SH TIV), also
nown as Fluvax® 2010 SH, was associated with an unexpected
ncrease in post-marketing reports of fever and febrile convulsions,
ompared to previous seasons, predominantly in children <5 years
f age. The adverse events were ﬁrst identiﬁed in April 2010 in the
tate of Western Australia during the third year of a government
ponsored paediatric inﬂuenza vaccination programme [3,4]. The
ate of febrile seizures (FS) was estimated to be as low as 3.3/1000
3] and as high as 5–7/1000 [4], with the majority occurring in
ealthy children (median age: 1.5 years) within 12 h of vaccina-
ion [5]. As would be expected with the age-related nature of FS,
S were not evident in children over 5 years of age or in adults
ollowing vaccination with the CSL 2010 SH TIV. In contrast, only
ne FS which was temporally associated with a TIV was reported
n Western Australia between 2008 and 2009, where cumulatively
7,946 children (26,037 in 2008 and 11,909 in 2009) were vacci-
ated [3]. Based on all the available post-marketing surveillance
nd clinical study data prior to the 2010 SH season, one could not
ave predicted the increase in reports of FS in children <5 years
hat were associated with the CSL 2010 SH TIV. CSL commenced a
horough and systematic investigation to determine the root cause
6,7]. The investigation had three discrete, but interlinking compo-
ents: (1) Clinical Safety Investigation to characterise the adverse
vent, identify risk factors and at-risk populations; (2) Manufac-
uring and Quality impact assessment of Safety, Quality, Identity,
urity and Potency to review all process parameters and process
ontrols which could have contributed to the adverse event; (3) A
cientiﬁc Program to identify the molecular mechanism and assess
he feasibility for in vitro or in vivo predictive tests to assist in future
accine production. A comprehensive review of all aspects of the
SL manufacturing process and quality attributes did not identify
ny changes or deviations from the previous seasons formulations
hat could explain the increase in reports of FS associated with the
SL 2010 SH TIV [6]. Furthermore, there was no change in the level
f the splitting agent (TDOC) used to prepare the CSL TIVs between
he 2009 and 2010 SH seasons [6].
Scientiﬁc investigations included exploration of several in vivo
nimal models, including non-human primates, ferrets, rabbits and
ewborn rats as potential models of fever and/or FS [6,7]. None
f the TIVs tested, including the CSL 2010 SH TIV, induced symp-
oms consistent with FS in any of the in vivo models examined.
n alternative approach was to utilise cytokine/chemokine release
rom paediatric whole blood as well as a NF-B HEK293 reporter
ssay as in vitro surrogate assays to investigate and identify the
oot cause of the increased fever and FS observed in a propor-
ion of children <5 years of age that were associated with the CSL
010 SH TIV. Although not deﬁnitive, the observation that indi-
iduals who have undergone FS frequently demonstrate elevations
n systemic cytokine levels, provides a logical basis for the use
f these in vitro models to evaluate the reactogenic potential of
IVs and MPHs. In this regard, cytokines and other immune medi-
tors have been implicated in either inducing fever or lowering
he threshold for FS in both animal models [8–10] and humans
11–20]. Pro-inﬂammatory cytokines are signiﬁcantly elevated in2 (2014) 3861–3868
the serum or central nervous system (CNS) of children following
FS, including those induced in response to inﬂuenza [11–17,19,20],
but rarely in fever only control groups suggesting that fever in the
absence of systemic cytokines is insufﬁcient to trigger FS. Further-
more, elevated levels of cytokines in the serum or CNS of children
with FS as compared to healthy controls, is also observed in vitro
using either unfractionated Whole Blood (WB) or Peripheral Blood
Mononuclear Cells (PBMC) [18]. It has been proposed that sys-
temic cytokine release in response to pyrogens may  be viewed as
pro-convulsant factors in children and FS as a state of active neuro-
inﬂammation [12,21–25]. The development and use of in vitro assay
systems to model and predict in vivo pyrogenicity induced by ther-
apeutic products is an evolving ﬁeld that is gaining acceptance
[26–29]. The present study has used several in vitro assays and iden-
tiﬁed that a small subset of paediatric whole blood donors displayed
elevated cytokine/chemokine responses to the CSL 2010 SH TIV (as
compared to previous CSL TIVs or other 2010 SH TIVs), with the
remainder displaying low cytokine/chemokine responses to all TIVs
tested. The scientiﬁc investigations have also provided insight into
the component(s) of the CSL 2010 TIV that potentially contributed
to the increase in reports of FS observed in 2010 as described in the
accompanying manuscript [30].
2. Materials and methods
2.1. TIV and MPH preparations tested
TIVs: CSL 2005/2006–2011/12 TIV (see Supplemental Table
1), CSL Panvax® monovalent H1N1, new CSL 2010 SH TIV
(where A/California/07/2009 replaced by A/Brisbane/59/2007),
licensed split virion 2010 SH TIV made by another man-
ufacturer (Comparator A), licensed sub-unit 2010/11 NH
TIV made by another manufacturer (Comparator B) and
MPHs: H1N1 (A/Brisbane/59/2007 and A/California/07/2009),
H3N2 (A/Uruguay/716/2007, A/Wisconsin/15/2009 and
A/Victoria/210/2009) and B strains (B/Brisbane/60/2008 and
B/Florida/04/2006) were tested in the in vitro assays with the
appropriate controls as described below.
2.2. Paediatric subjects and in vitro whole peripheral blood
assays (WBA)
Healthy children aged 1–10 years undergoing an elective surgi-
cal procedure at the Royal Children’s Hospital, Melbourne, Australia
were eligible for the study. EDTA whole blood samples were
aliquoted into 48-well tissue culture plates, diluted ½ in Dulbecco’s
PBS and cultured in duplicate, in the presence of either a test vaccine
(TIV, ﬁnal dilution 1/10), its MPH  components (10.6 g HA/mL), TIV
diluent (Nil control) or Endotoxin (USP, Merck, 11.1 EU/mL). See
Supplemental Materials and Methods for further details.
2.3. In vitro NFB HEK293 reporter assay
The NF-B/SEAPorter HEK293 cell line (NF-B HEK 293) was
maintained in the presence of selection agents according to
manufacturer’s instructions (Imgenex Corp., USA). For in vitro stim-
ulation, cells were seeded into 96 well plates at a cell density of
4 × 104 cells/well and 16 h later, TIV or MPH  added to a ﬁnal concen-
tration of 10.6 g/mL HA in a volume of 200 L (or 2.12 gHA/well).
See Supplemental Materials and Methods for further details.
2.4. Statistical analysisA data set comprising protein concentrations of 21
cytokines/chemokines from WBA  of 9 donors stimulated with
14 stimuli and Nil control, and 1 donor stimulated with 13 stimuli
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Fig. 1. Induction of cytokines/chemokines in response to CSL and Comparator TIVs
following stimulation of paediatric whole blood cells in vitro. Paediatric whole blood
was stimulated for 24 h with either CSL or Comparator TIVs at a ﬁnal concentration
of 10.6 g/mL total HA. Cluster analysis and responses of 21 cytokines/chemokines
of  10 donors are shown as log-transformed and contrasted to Nil. The x-axis values,
and their respective colours, are log fold changes with respect to Nil (control). The
colour blocks are: blue (−2 to −1), black (−1 to 1), and red (1–4). The values smallerS. Rockman et al. / Va
nd Nil control was analysed. Statistical analyses were performed
n log-transformed cytokine/chemokine concentration data using
MP  statistical software (version 9.0.1). See supplemental Materials
nd Methods for further details.
. Results
Initial studies suggested that CSL’s standard TIV manufacturing
rocess, in combination with strain-speciﬁc characteristics associ-
ted with the three new strains introduced into the 2010 SH TIV
ontributed to the increase in reports of FS in children <5 years
ssociated with the CSL 2010 SH TIV (reviewed [5]). To test this
ypothesis, a series of in vitro studies, were performed to identify
he component(s) within the CSL 2010 SH TIV that may  have con-
erred this pyrogenic potential. In addition, for the 2010 SH season,
he WHO  recommended three new strains be used in the seasonal
accine. To assess the potential contribution of the novel H1N1 pan-
emic strain, A/California/07/2009, a TIV was generated whereby
he A/California/07/2009 H1N1 strain was replaced with the pre-
ious H1N1 strain (A/Brisbane/59/2007) (referred to as New CSL
010 SH TIV).
.1. Comparison of responses to CSL TIVs and MPHs in paediatric
hole Blood Assays (WBA)
Initial examination of cytokine/chemokine induction in in vitro
BAs from 10 paediatric donors demonstrated that, in general,
he CSL TIVs, irrespective of whether they were associated with
S (CSL 2010 SH TIV) or not (CSL 2009 SH or CSL 2009/10 NH
IV) elicited higher levels of cytokines/chemokines in vitro as com-
ared to responses induced by 2010 SH TIVs produced by other
anufacturers (Comparator A and B TIVs) (Table 1 and Fig. 1).
his increased cytokine/chemokine response was  signiﬁcant for all
ytokine/chemokines with the exception of GRO, when CSL 2010
H TIV was compared to Comparator A 2010 SH TIV or Compara-
or B 2010/11 NH TIV (Table 1). These data indicated that CSL’s
IVs, as a class, were more potent inducers of cytokines in vitro,
s compared to Comparator TIVs. Comparison of the CSL 2010 SH
IV with previous seasons CSL 2009 SH TIV (using the geometric
eans of the various cytokines/chemokines from the 10 paedi-
tric donors) identiﬁed a small number of cytokines/chemokines
hat were differentially elevated following stimulation with the
SL 2010 SH TIV (e.g. IL-1, IL-6, IL-8, G-CSF, MCP-3) however,
hese were trends rather than signiﬁcant differences. The only
ytokines/chemokines that were signiﬁcantly elevated in response
o the CSL 2010 SH TIV as compared to the CSL 2009 SH TIV were
-CSF with MCP-3 secretion approaching signiﬁcance (Table 1 and
ig. 1). Furthermore, there was a trend for the New CSL 2010 SH
IV (A/California/07/2009 replaced by A/Brisbane/59/2007) to elicit
educed levels of G-CSF, IL-1, IL-8 and Gro-1, suggesting a poten-
ial contribution of the A/California/07/2009 H1N1 strain towards
he elevated cytokines/chemokine levels (Fig. 1). The overall lack
f a statistically signiﬁcant difference between the CSL 2010 SH
IV and the CSL 2009 SH TIV (also reported by Blyth et al. using
aediatric PBMCs [5]) or the CSL 2009/10 NH TIV was primar-
ly due to the wide donor-to-donor variation in the magnitude of
ytokine/chemokine levels induced. Of note was the presence of
 distinct cluster of high responding paediatric donors amongst
 majority of low responding donors. This difference was further
valuated by stratifying the paediatric donors into those whose
esponses to the CSL 2010 SH TIV were either above or below
he mean levels of cytokines/chemokines tested. When viewing
he data in this way, a cluster of high responders, representing
pproximately 30% of donors tested, was identiﬁed (Fig. 2). The
igh responders demonstrated a statistically signiﬁcant differencethan −2 and greater than 4 are shown as −2 and 4 respectively. The y-axis values
give the histogram height, which indicates the distribution of the corresponding
values/colours in the heat map.
in several cytokine/chemokines in response to the CSL 2010 SH TIV
as compared to the previous season’s CSL 2009 SH TIV or the CSL
2009/10 NH TIV (Fig. 2). Such differences were not observed within
the low responders (Fig. 2). This analysis indicated that a subset
of paediatric donors responded more vigorously to the CSL 2010
SH TIV when compared to previous season’s CSL TIVs suggesting
that this subset of donors was particularly sensitive to compo-
nents within the CSL 2010 SH TIV as compared to previous season’s
CSL TIVs. As shown in Fig. 2, the New CSL 2010 SH TIV elicited a
diminished cytokine/chemokine secretion proﬁle, particularly in
the high responding paediatric blood donors, indicating a potential
contribution of the A/California/07/2009 H1N1 strain towards the
elevated cytokines/chemokine levels.
Closer examination of the MPH  viral strains used in the CSL
2010 SH TIV indicated that the H1N1 (A/California/07/2009) and
B (B/Brisbane/60/2008) strains, and to a much lesser extent, the
H3N2 strain (A/Wisconsin/15/2009) were the major inducers of
pro-inﬂammatory cytokines/chemokines in the paediatric WBAs
(Figs. 3 and 4). The H1N1 strain, A/Brisbane/59/2007 (used in
the CSL 2009 SH and CSL 2009/10 NH TIVs) was a weak inducer
of cytokine/chemokines in the paediatric WBAs (Figs. 3 and 4).
Interestingly, both B/Florida/04/2006 (used in the CSL 2009 SH
TIV) and B/Brisbane/60/2008 (used in the CSL 2009/10 NH and
CSL 2010 SH TIV) elicited strong cytokine/chemokine signals with
a trend for B/Brisbane/60/2008 to elicit higher cytokine signals
than the previous B/Florida/04/2007 strain (e.g. increased G-CSF,
IFN-2, IL-1, TNF- and decreased IL-8 and IL-10) (Fig. 3).
Similarly, H3N2 A/Wisconsin/15/2009 appeared to elicite higher
levels of MIP-1,  MIP-1,  IP-10 and IL-1 than the previous
3864 S. Rockman et al. / Vaccine 32 (2014) 3861–3868
Table 1
Fold increase in cytokine/chemokine GMC  for CSL 2010 SH TIV compared to CSL 2009 SH TIV, Comparator A or Comparator B (p < 0.05 considered signiﬁcant, signiﬁcant
increases in bold).
Cytokine 2009 SH TIV 2010 Comparator A 2010 Comparator B
Fold increasea p value Fold increaseb p value Fold increasec p value
IL-1 3.23 0.1 7.84 <0.0001 29.89 <0.0001
IL-6  1.85 0.7 3.97 0.0011 12.79 <0.0001
TNF-  1.41 0.9 2.14 0.0154 4.29 <0.0001
IL1-RA 1.67 0.8 7.58 <0.0001 10.23 <0.0001
MIP-1  1.17 >0.9 3.42 0.0013 7.53 <0.0001
MIP-1  1.21 >0.9 2.64 0.0036 4.93 <0.0001
GRO  1.09 0.9 0.88 >0.9 1.51 0.5
IP-10 1.96 0.7 30.63 <0.0001 43.15 <0.0001
MCP-1 1.75 0.2 5.71 <0.0001 5.36 <0.0001
MCP-3 2.07 0.07 4.38 <0.0001 4.34 <0.0001
IFN2  1.3 >0.9 1.98 0.0107 2.72 <0.0001
GCSF  2.27 0.0473 3.61 <0.0001 3.33 0.0001
a Fold increase = GMC  (CSL 2010 SH TIV) ÷ GMC  (CSL 2009 SH TIV).
b Fold increase = GMC  (CSL 2010 SH TIV) ÷ GMC  (Comparator A).
c Fold increase = GMC  (CSL 2010 SH TIV) ÷ GMC  (Comparator B).
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Fig. 2. Induction of cytokines/chemokines in response to CSL and Comparator TIVs following stimulation of paediatric whole blood cells in vitro. Paediatric whole blood was
stimulated for 24 h with either CSL or Comparator TIVs at a ﬁnal concentration of 10.6 g/mL HA. Individual responses as well as the geometric mean concentration (GMC)
of  IL-1, IL-6, IP-10, TNF-, MCP-3/CCL7 and Gro for all 10 paediatric donors are presented (dotted line). High responders (bold black line) and low responders (thin black
line)  were deﬁned as those whose cytokine/chemokine readout was above or below the GMC in response to the CSL 2010 SH TIV respectively.
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Fig. 3. Induction of cytokines/chemokines in response to CSL-generated H1N1,
H3N2 and B strain MPHs following stimulation of paediatric whole blood cells
in  vitro. Paediatric whole blood was stimulated for 24 h with CSL MPHs at
a  ﬁnal concentration of 10.6 g/mL HA. Cluster analysis and responses of 21
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mytokines/chemokines of 10 donors are shown as log-transformed and contrasted
o  Nil. MPHs present in either CSL 2009 SH TIV or CSL 2010 SH TIV are highlighted.
olour key and histogram for heat map  as described in Fig. 1.
easons A/Uruguay/716/2007 (Fig. 3). As observed with the TIVs
n Fig. 2, there was a distinct cluster of paediatric donors whose
ytokine/chemokine responses were particularly elevated to the B
trains as well as to the H1N1 A/California/07/2009 strain (Fig. 4).
.2. Comparison of responses to CSL TIVs and MPHs in the NF-B
EK293 reporter assay
The pro-inﬂammatory potential of the CSL 2010 SH TIV and its
PH  components was also examined using the NF-B HEK 293 (NF-
B representing a master regulator of several pro-inﬂammatory
ytokine responses). As shown in Fig. 5, the NF-B reporter
esponses paralleled the cytokine/chemokine signals observed in
he paediatric WBAs, with the strongest signal induced by the CSL
009/10 NH, CSL 2010 SH and CSL 2010/11 NH TIVs, but not the
SL 2009 SH TIV nor the Comparator A TIV (Fig. 5). Examination
f the MPH  strains indicated that B/Brisbane/60/2008 induced the
trongest NF-B signal followed by B/Florida/04/2006, with little
o no NF-B response induced by the H1N1 MPHs, or H3N2 MPHs
Fig. 5).
.3. Increased NF-B signalling associated with the CSL TIVs
oincides with the inclusion of the B/Brisbane/60/2008 strainCSL SH and NH TIVs from the 2005/06 NH season to the 2011/12
H seasons were assessed in the NF-B HEK 293 cell assay to deter-
ine whether the NF-B signal was present in previous CSL TIVs,2 (2014) 3861–3868 3865
or that a signal emerged more recently with the introduction of a
new strain(s). As shown in Fig. 6, there was negligible NF-B signal
induced by CSL TIVs from the 2005/06 NH season up until the 2009
SH season. The ﬁrst CSL TIV that induced a notable NF-B signal in
the NF-B HEK 293 cells was the CSL 2009/10 NH TIV. This coincides
with the ﬁrst introduction of the B/Brisbane/60/2008 strain. This B
strain has remained in subsequent seasonal TIVs, as has the capac-
ity of subsequent B/Brisbane/60/2008-containing TIVs to induce an
NF-B signal in the NF-B HEK 293 cells (Supplemental Table 1).
4. Discussion
In the 2010 SH season, the CSL 2010 SH TIV (also known as
Fluvax® 2010 SH), was  associated with an unexpected increase
in post-marketing reports of fever and FS, compared to previous
seasons, predominantly in children <5 years of age. The Australian
Therapeutics Good Administration (TGA) cited the rate of FS to be
5–7 per 1000 doses [4]. Prior to the 2010 events, CSL’s TIV had
not been associated with a signiﬁcant risk of FS. Clinical data that
emerged after these reports, showed CSL’s TIV to be associated with
a higher rate of fever in the paediatric population as compared
to at least one other marketed inﬂuenza vaccine, however these
fevers were predominantly mild and moderate [31,32]. Only one
child experienced FS following the ﬁrst vaccination with CSL’s TIV
in the total clinical trial exposure of 1083 children aged 6 months
to <3 years. In addition, only one FS which was  temporally associ-
ated with a TIV, was  reported in Western Australia between 2008
and 2009 during the WAIVE studies (which included TIVs from 3
manufacturers) [3]. In all cases, the rate of occurrence of FS was
consistent with the expected background rate of FS in children in
this age group. Thus, the increase in post-marketing reports of FS
observed in children <5 years, who  received the CSL 2010 SH TIV,
could not have been predicted from either the clinical trial data or
the post marketing reports generated in the paediatric population
prior to the 2010 SH season.
Extensive investigations into CSL’s manufacturing processes
have not identiﬁed any changes or deviations between the 2009
SH season and the 2010 SH season that would explain the increase
in reports of FS associated with the CSL 2010 SH TIV. Importantly,
this analysis, which included a variety of approaches to detect
bacterially derived pyrogens (e.g. rabbit pyrogenicity, LAL and
myelomonocytic cell line tests performed by CBER/NIAID) enabled
endotoxin to be conclusively ruled out as the root cause, thus sug-
gesting that the pyrogenic signal in the CSL 2010 SH TIV was likely
of viral origin. The fact that FS were not associated with either 2010
SH TIVs made by other manufacturers or by CSL TIVs from previous
seasons, also suggests that the root cause may  involve a combi-
nation of CSL’s standard method of manufacture and differences
in how components of the new strains used in the 2010 SH season
were expressed in the CSL 2010 SH TIV. In this regard, it is likely that
in the 2010 SH season, the particular characteristics of one or more
of the new strains used in the CSL TIV possibly increased the biolog-
ical activity of the CSL 2010 SH TIV over a threshold, contributing
to the increase in reports of FS in some children <5 years.
Given that the various TIVs tested were unable to elicit a fever
response in animal models (rabbit, mice, ferrets, infant non-human
primates and new born rats) [6], the investigations turned to the
use of in vitro cytokine and chemokine induction models as corre-
lates of in vivo pyrogenicity, which may  act as an indirect surrogate
measure of the TIV’s reactogenic potential. Using paediatric (shown
in present manuscript) and adult (data not shown) whole blood
in vitro assays, we have shown that CSL TIVs, as a class, induce
higher levels of inﬂammatory cytokine/chemokine responses when
compared to year and strain matched TIVs made by other manu-
facturers (Comparator A 2010 SH and Comparator B 2010/11 NH
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IVs). However, in a subset of paediatric donors, the CSL 2010
H TIV induced even higher cytokine/chemokine responses than
ere induced by CSL TIVs from previous seasons (e.g. CSL 2009
H or 2009/10 NH TIVs). This observation suggests inherent sen-
itivities of some paediatric donors (<5 years), but not others, to
omponents within the CSL 2010 SH TIV as compared to previ-
us season’s CSL TIVs. It is of note that only a small proportion
f children <5 years manifested FS. Whether this is due to genetic
ariations between individuals (e.g. polymorphisms in genes that
ither positively or negatively regulate immune responses) that
ay lower the threshold for immune reaction and potentially
mpact the likelihood of a fever response [33–38] is unclear,
ut individual immunogenetics are emerging as contributing fac-
ors to adverse reactions to vaccination [37]. Closer examination
f B/Brisbane/60/2008 and H1N1 A/California/7/2009 (Swine Flu)
PHs manufactured by CSL demonstrated that these particu-
ar strains were more highly stimulatory of cytokine/chemokinend B strain MPHs following stimulation of paediatric whole blood cells in vitro.
 a ﬁnal concentration of 10.6 g/mL HA. The geometric mean concentration (GMC
resented. Responses of individual donors are also shown as individual symbols.
production in the in vitro cell-based assays examined, as com-
pared to the H3N2 strains tested (e.g. A/Uruguay/716/2007,
A/Wisconsin/15/2009, A/Victoria/210/2009). Once again a small
subset of paediatric donors displayed elevated responses to these
strains as compared to the majority of paediatric donors tested
suggesting inherent sensitivities to components of these strains as
expressed through the CSL method of manufacture.
An intriguing ﬁnding following the testing of a collection of CSL
TIVs spanning the period from and including the 2005/06 NH season
to the 2011/12 NH season, was  that the ﬁrst detection of an NF-
B signal, coincided with the introduction of B/Brisbane/60/2008
in the 2009/10 NH season. This signiﬁcant NF-B signal has per-
sisted in subsequent CSL seasonal TIVs, all of which contain the
B/Brisbane/60/2008 strain (i.e. CSL 2010 SH, CSL 2010/11 NH, CSL
2011 SH, CSL 2011/12 NH). Although there were no reports of FS
in children receiving the CSL 2009/10 NH TIV, results from the
07-36 US Post-Licensure study, that became available after the FS
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ignal was observed in 2010, showed the CSL 2009/10 NH TIV to be
ssociated with a higher rate of mild to moderate fever (but not FS)
eported in children <5 years as compared to another split virion TIV
ested [31]. Although the introduction of the B/Brisbane/60/2008
ig. 6. NF-B signalling capacity in the SEAPorter HEK 293 cell assay of CSL TIVs from the
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strain within the CSL manufacturing process (such as occurred in
the preceding 2009/10 NH season) appears to have raised the pyro-
genic potential of the CSL 2009/10 NH TIV, this was insufﬁcient to
elicit FS at the same rate as the CSL 2010 SH TIV in children <5 years.
Why  then was the CSL 2010 SH TIV associated with an increase in
reports of FS in children <5 years when events of this nature were
rare in previous seasons [6]. The 2010 SH season coincided with the
ﬁrst introduction of the H1N1 A/California/07/2009 in combination
with the B/Brisbane/60/2008 strain. Our data also demonstrates
that the introduction of at least the H1N1 A/California/07/2009
strain and to a much lesser degree, the A/Wisconsin/15/2009 (both
present within the CSL 2010 SH TIV but absent from the preceding
CSL TIVs) into the CSL 2010 SH TIV combined and likely com-
pounded the bioactivity of the CSL 2010 SH TIV. This was associated
with stronger immune responses, which in a proportion of children
<5 years were associated with FS. The data are consistent with the
working hypothesis that factors present in the 2010 SH TIV (which
were absent in the previous season’s CSL 2009/10 NH TIV) altered
the biologic behaviour of the CSL 2010 SH TIV to be associated with
more severe adverse events than previously reported.
Studies to identify the vaccine components(s) in CSL 2010 SH
TIV that may  have contributed to FS in children, and to further
investigate process changes that could possibly reduce them are
described in an accompanying manuscript [30]. The assays and sys-
tems developed during these investigations should greatly assist in
determining the bioactivity of new inﬂuenza strains, and thus aid
with the manufacture of CSL TIVs indicated for use in the paediatric
population.
 CSL 2005/06 NH to the current season’s CSL 2011/12 NH TIVs. Induction of NF-B
IVs from the 2005/06 NH to 2011/12 NH seasons (H1N1, H3N2 and B strain MPH
nd shown as a black bar graph. All samples were tested in triplicate at 24 h.
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